Supplementary Material for: Effect of Bilastine on Chronic Urticaria: A Systematic Review and Meta-Analysis

Background: Allergic diseases are a public health problem with the largest number of patients and the widest age distribution. Chronic urticaria (CU) is a common clinical allergic disease. Bilastine is effective in the treatment of CU, especially skin wind masses and erythema. The purpose of this study was to systematically evaluate the efficacy and safety of Bilastine in the treatment of CU symptoms and to provide an evidence-based reference for clinical rational drug use. Methods: PubMed, Scopus, the Cochrane Library, Embase, EBSCO, and other databases were searched by computer to collect the trials on the effect of bilastine on patients with CU. The retrieval time limit was established until November 2021. Two researchers independently screened the literature, extracted data, and evaluated the risk of bias in the included study. Meta-analysis was performed using RevMan5.4 software. Results: A total of 7 studies were included, including 975 patients. Meta-analysis results showed that compared to the control group, bilastine significantly improved the skin quality of life index, Total Symptom Score (TSS), and weekly urticaria activity score. The skin quality of life index DLQI score (MD = −4.98, 95% CI: −8.09 to −1.86, p = 0.002), skin symptom score TSS (MD = −1.62, 95% CI −2.29 to −0.94, p p Conclusions: Bilastine has a better therapeutic effect on CU and can also significantly improve the clinical symptoms and quality of life of CU.

背景：过敏性疾病是患病人数最多、年龄分布最广的公共卫生问题。慢性荨麻疹（Chronic Urticaria，CU）为临床常见过敏性疾病。比拉斯汀（Bilastine）在治疗慢性荨麻疹，尤其是皮肤风团与红斑方面疗效确切。本研究旨在系统评价比拉斯汀治疗慢性荨麻疹症状的疗效与安全性，为临床合理用药提供循证参考。方法：通过计算机检索PubMed、Scopus、Cochrane图书馆、Embase、EBSCO等数据库，收集比拉斯汀治疗慢性荨麻疹患者的相关临床试验，检索时限截至2021年11月。由2名研究者独立完成文献筛选、数据提取及纳入研究的偏倚风险评价。采用RevMan5.4软件进行Meta分析。结果：最终纳入7项研究，共计975例患者。Meta分析结果显示，与对照组相比，比拉斯汀可显著改善皮肤病生活质量指数（Dermatology Life Quality Index，DLQI）、总症状评分（Total Symptom Score，TSS）及每周荨麻疹活动评分。其中皮肤病生活质量指数DLQI评分（均差MD=-4.98，95%置信区间CI：-8.09至-1.86，p=0.002）、皮肤症状总评分TSS（均差MD=-1.62，95%CI：-2.29至-0.94，p p）结论：比拉斯汀对慢性荨麻疹具有更优的治疗效果，同时可显著改善慢性荨麻疹患者的临床症状与生活质量。